Why Summit Therapeutics Stock Is Trading 8% Higher Monday
Why Summit Therapeutics Stock Is Trading 8% Higher Monday
Summit Therapeutics, Inc. (NASDAQ:SMMT) stock is moving higher Monday following the company's announcement that it received marketing authorization in China for ivonescimab in combination with chemotherapy.
納斯達克（NASDAQ）：康方生物（Akeso）贊助的第三期HARMONi-A臨床試驗數據表明，ivonescimab用於某些類型的晚期非小細胞肺癌的聯合治療的總有效率爲50.6％，相較於僅接受化療的人群爲35.4％。該研究還表明，ivonescimab與化療聯合使用可將疾病進展的風險減少54％。 週一，峯峯藥業（Summit Therapeutics）宣佈，在中國獲得ivonescimab聯合化療藥物的上市授權，推動了該股票的上漲。
What Happened: Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization.
具體來說，根據由康方生物贊助的第三期HARMONi-A臨床試驗數據，該研究顯示ivonescimab在治療某些癌症方面有着良好的實驗結果後，中國授予了Summit的上市授權。
Specifically, the clinical trial included patients with certain types of advanced non-small cell lung cancer. The overall response rate for the combined treatment was 50.6% compared to 35.4% for those only receiving chemotherapy.
該臨床試驗針對晚期非小細胞肺癌患者進行，應用聯合治療總體有效率比僅接受化療的人群高出15.2%。
In addition, the study showed that ivonescimab in combination with chemotherapy led to a 54% reduction in the risk of disease progression compared to chemotherapy.
此外，該研究還表明，ivonescimab與化療聯合使用可將疾病進展的風險減少54％，相較於僅接受化療的人群。
"We are excited to continue to develop ivonescimab with appropriate, accelerated pace and with the intent to make a significant difference for those patients who may benefit most from new, innovative therapies in lung cancer and other solid tumors," added Dr. Maky Zanganeh, CEO and president of Summit.
Summit的首席執行官兼總裁Maky Zanganeh博士表示：“我們很高興能夠以適當而加速的速度繼續開發ivonescimab，目的是在肺癌和其他實體瘤治療領域爲那些最有可能受益於新型創新療法的患者帶來重要的不同。”
Separately, Summit announced that it accepted an unsolicited offer from an institutional investor to buy 22 million shares of its common stock at $9.00 each, raising $200 million in gross proceeds.
此外，峯峯藥業還宣佈，接受了一家機構投資者以每股9.00美元的價格購買其普通股2200萬股的無意向性收購，募集了2億美元的總收益。
The company intends to use the proceeds in part to continue the development of invonescimab. Summit also intends to use the funds as working capital and for general corporate purposes.
峯峯藥業擬將募集的資金用於繼續發展ivonescimab，同時還將用於營運資本和企業一般用途。
Related Link: Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
相關鏈接：愛文思控股發佈晚期Donidalorsen數據，分析師表示結果顯示競爭性的遺傳性血管性水腫概況
SMMT Price Action: Summit Therapeutics shares are trading 8.12% higher at $9.39, according to data from Benzinga Pro.
根據Benzinga Pro的數據，峯峯藥業的股票價格上漲8.12％至9.39美元。
Image: 3139127 from Pixabay.
圖片來源：Pixabay的3139127。
譯文內容由第三人軟體翻譯。